David Emanuelson | People | Arnold & Porter

David Emanuelson, former Chief M&A Regulatory Counsel and Associate General Counsel for Intel Corporation, is a member of the firm’s Antitrust/Competition practice. He advises clients on merger analysis, complex private antitrust litigation, government investigations, and antitrust compliance in the technology and life sciences industries.

David has deep experience in M&A regulatory issues involving the intersection of antitrust and national security, including CFIUS, ex-U.S. foreign direct investment, and U.S. export control issues. He is one of the few antitrust lawyers outside of China with significant experience directly interacting with the Chinese regulatory authority (SAMR).

In his prior role as Head of Antitrust Americas for a multinational pharmaceutical corporation, he handled complex antitrust litigation, government investigations and merger analysis, with an emphasis on issues involving the intersection of antitrust and intellectual property.

Prior to his in-house experience, David spent over a decade in private practice representing clients in complex antitrust litigation and government investigations in the microprocessor, chemicals, telecommunications, airline, television, dairy, and automotive refinishing paint industries.

Focus Areas

Experience

Led Intel’s global regulatory team securing worldwide regulatory approvals for its US$9 billion sale of its NAND memory business to SK hynix.
Led Intel’s global regulatory team in its proposed US$5.4 billion acquisition of Tower Semiconductor.
Advised Intel’s corporate venture capital arm (Intel Capital) on regulatory issues and antitrust compliance for minority investments.
Handled multiple government investigations involving merger review, abuse of dominance, and standard setting practices in the technology industry, appearing in front of the Federal Trade Commission, U.S. Department of Justice, European Commission, SAMR, and numerous other international authorities.
Successfully litigated complex commercial litigation as Associate General Counsel in Intel’s Commercial Litigation group.

For a multinational pharmaceutical company, led the Americas regulatory teams securing merger clearance for multiple multi-billion dollar transactions from 2013-2017.
Led team that successfully litigated sham litigation case related to Hatch-Waxman Act patent settlement for multinational pharmaceutical company.
Developed and oversaw antitrust compliance processes for Hart-Scott-Rodino filings, Hatch-Waxman Act patent settlement practices, and lifecycle management strategies.
Successfully argued in front of the 7th Circuit in pro bono matter, securing reversal of criminal conviction.